Ruxolitinib in myelofibrosis: to be or not to be an immune disruptor.

about

Infections associated with ruxolitinib: study in the French Pharmacovigilance database.

P2860

Q48230479-CAAF09D5-E209-4B42-A4BE-C182004855FC

P2860

Ruxolitinib in myelofibrosis: to be or not to be an immune disruptor.

Item

http://www.wikidata.org/entity/Q38938526

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Ruxolitinib in myelofibrosis: to be or not to be an immune disruptor.

@en

type

Item

label

Ruxolitinib in myelofibrosis: to be or not to be an immune disruptor.

@en

prefLabel

Ruxolitinib in myelofibrosis: to be or not to be an immune disruptor.

@en

P1476

Ruxolitinib in myelofibrosis: to be or not to be an immune disruptor

@en

P2093

Palma Manduzio

http://www.w3.org/2001/XMLSchema#string

P2860

Janus kinase-1 and Janus kinase-2 inhibitors for treating myelofibrosis

Role of tyrosine-kinase inhibitors in myeloproliferative neoplasms: comparative lessons learned

Klebsiella pneumoniae: Going on the Offense with a Strong Defense

Management of Epstein-Barr Virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelines

Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib

The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)

Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.

Predictors of mortality and differences in clinical features among patients with Cryptococcosis according to immune status

The antimicrobial therapy puzzle: could pharmacokinetic-pharmacodynamic relationships be helpful in addressing the issue of appropriate pneumonia treatment in critically ill patients?

P304

169-177

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/TCRM.S121683

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Palma Manduzio

P577

2017-02-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28243106

http://www.w3.org/2001/XMLSchema#string

P932

5315213

http://www.w3.org/2001/XMLSchema#string

Ruxolitinib in myelofibrosis: to be or not to be an immune disruptor.

about

P2860

P2860

Ruxolitinib in myelofibrosis: to be or not to be an immune disruptor.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P50

P577

P698

P932